Injectable Human Growth Hormone Peptide Cjc1295 with Dac 2mg/Vial

High quality Injectable Peptide Lyophilized Powder CJC-1295

Quick Detail:

product descroption: 

Research study participants for often cycle doses 2-3 times per day (ex: before breakfast, before bed, and after exertion) for a period up to several weeks. These cycles, or pulses are meant to closely mimic natural secretion of GH. For CJC 1295, dosing is less frequent since the half-life with DAC is up to 8 days. Therefore, the cycle for CJC 1295 with DAC calls for once weekly injections that result in an overall increase of secretion of GH. At this point, research does not show any significant advantage for one cycle over the other, so it is a matter of personal preference.

CJC-1295 Application

CJC 1295 without DAC is a 30 amino acid peptide hormone, better known in the community as a GHRH (growth hormone releasing hormone). Essentially, what this means is this peptide will release a series of pulses over a long period of time which usually equates to fewer injections. Even though CJC 1295’s main function upon creation was found to boost protein synthesis, increased growth of muscle tissue and many other benefits come with it as well. CJC 1295 also helps injury recovery times, reduce body fat, boost immune system and bone density and cellular repair (skin and organs). To clear up many misconceptions, let’s get the semantics out of the way from the beginning. CJC 1295 without DAC is not CJC-1295, but is misnamed Mod GRF. When a peptide doesn’t include DAC it’s really not CJC 1295 but commonly called so. Here is a visual of MOD GRF (CJC 1295 no DAC)

CJC 1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.

At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 1000 mcg dose would require a volume of 1 mL, or “100 IU” as marked on an insulin syringe.

CJC-1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).